06/22/22 7:00 AMNasdaq : ATHA clinical trialAthira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s DiseasePrimary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of fosgonimeton and standard-of-care (AChEIs) given together showed potential diminished effect of fosgonimeton A pre-specified subgroup analysis of patients onRHEA-AIneutral
06/07/22 7:00 AMNasdaq : ATHA managementAthira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology ResearchAthira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the formation of a Scientific Advisory Board (SAB)RHEA-AIneutral
05/19/22 12:06 PMNasdaq : ATHA Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual MeetingAthira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced, based on the preliminary vote count provided by itsRHEA-AIvery positive
05/16/22 4:49 PMNasdaq : ATHA Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy ContestAthira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceuticalRHEA-AIvery positive
05/16/22 8:00 AMNasdaq : ATHA managementRic Kayne Suspends Campaign to Elect Himself and George Bickerstaff to Athira Pharma Board of DirectorsRichard A. Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc., today issued the following letter to Athira shareholders. I started my campaign for change at Athira Pharma, Inc. in February 2022, nominating myself and George Bickerstaff, to the Athira Board of Directors...RHEA-AIneutral
05/16/22 7:00 AMNasdaq : ATHA clinical trialAthira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual MeetingAthira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health andRHEA-AIneutral
05/12/22 4:05 PMNasdaq : ATHA earningsAthira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business UpdatesAthira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health andRHEA-AIvery positive
05/12/22 8:00 AMNasdaq : ATHA Ric Kayne Issues Letter to Athira Shareholders Highlighting Need for Immediate Change to Athira BoardRichard A. Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc., today issued a letter to Athira shareholders outlining numerous, value-destructive missteps by the current Board of Directors, and detailing why immediate change to the Board at the 2022 annual meeting of...RHEA-AIneutral
05/11/22 4:15 PMNasdaq : ATHA Athira Urges Shareholders to Support its Director Nominees at May 19 Annual MeetingAthira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stageRHEA-AIneutral
05/09/22 7:00 AMNasdaq : ATHA clinical trialAthira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s DiseaseAthira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal healthRHEA-AIneutral